AI Summary Stivarga (regorafenib) is an oral multikinase inhibitor used for hepatocellular carcinoma previously treated with sorafenib.
Medically reviewed.
Stivarga (regorafenib) is a prescription targeted therapy used to treat certain cancers, including hepatocellular carcinoma (HCC) that was previously treated with sorafenib. It belongs to a class of medications called multikinase inhibitors, which block proteins involved in cancer growth and blood vessel formation. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Stivarga's role in liver cancer management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Stivarga fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT STIVARGA TREATMENT
Stivarga is a prescription medicine that contains regorafenib, a type of medication known as a multikinase inhibitor. It blocks proteins called kinases that are involved in cancer growth and in the formation of blood vessels that feed tumors.
Stivarga is used to treat certain cancers, including hepatocellular carcinoma (HCC) that was previously treated with sorafenib. It is a second-line systemic treatment, which means it is used after an earlier medicine has been tried.
Stivarga comes as an oral tablet. It is typically used alongside regular monitoring by your healthcare provider, including Liver Function Tests (LFTs), blood pressure checks, and reviews of how the treatment is working.
WHO STIVARGA MAY BE SUITABLE FOR
Eligibility for Stivarga depends on your diagnosis, the treatments you have already had, and your individual health needs. Your healthcare provider may consider Stivarga if you have HCC that was previously treated with sorafenib, your liver cancer has progressed despite prior therapy, and you need second-line systemic treatment.
Your provider will also consider whether you are a candidate for targeted therapy and whether Stivarga can help slow your disease progression.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Stivarga. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver cancer, liver function, and treatment goals.
ELIGIBILITY OVERVIEW
Stivarga may be considered for adults with the following conditions or treatment goals:
Before recommending Stivarga, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW STIVARGA CAN HELP
Stivarga blocks several kinases, the proteins that help cancer cells grow and divide. It also blocks the formation of blood vessels inside tumors, which tumors need to grow.
By blocking these signals, Stivarga reduces cancer cell growth and slows disease progression. This helps control advanced liver cancer.
For people with HCC that was previously treated with sorafenib, these effects can support a treatment goal of delaying progression. Stivarga is not used on its own: providers pair it with regular monitoring of liver function, blood pressure, and treatment response.
LIVER CANCER BENEFITS
Stivarga is a multikinase inhibitor. Kinases are proteins that send growth signals inside cancer cells, and Stivarga blocks several of them at the same time. When these signals are blocked, cancer cells divide less often. This reduces cancer cell proliferation, which means fewer new cancer cells are made. Because the medicine acts on more than one kinase, it does not depend on a single pathway to work.
Tumors need their own blood vessels to bring in oxygen and nutrients so they can grow. Stivarga inhibits the formation of blood vessels within tumors, which limits the supply the tumor relies on. This is called anti-angiogenic activity. Together with the blocking of growth signals, it gives Stivarga two ways to act against the cancer.
Because Stivarga acts on several growth pathways at once, it helps slow disease progression and helps control advanced liver cancer. Slowing progression means the cancer grows or spreads more gradually than it would without treatment. Stivarga is not a cure, and the benefit varies from person to person. It depends on the cancer, your liver function, and how well your body tolerates the medicine.
Liver cancer therapies such as Stivarga are used when surgery or local treatments are not appropriate or when the cancer has spread. Stivarga gives people whose HCC was previously treated with sorafenib another systemic treatment option. It may be considered when liver cancer has progressed despite prior therapy. Your provider weighs the stage of your cancer, your liver function, your blood pressure, your overall health, and your treatment goals before recommending it.
Stivarga blocks several pathways that drive liver cancer growth and may help slow progression in people previously treated with sorafenib. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Stivarga comes as an oral tablet. Take it exactly as prescribed.
The usual dose is 160 mg once daily for the first 21 days of each 28-day cycle. Your healthcare provider determines the right dose for you.
Take Stivarga with a low-fat meal at about the same time each day.
Stivarga is used as ongoing cyclic therapy for advanced HCC. It continues until the disease progresses or side effects become unacceptable. Duration is individualized based on your response and how well you tolerate it.
Store Stivarga at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor your liver function, blood pressure, and treatment response.
BENEFITS AND SAFETY
Stivarga (regorafenib) may support people with advanced hepatocellular carcinoma that was previously treated with sorafenib. It blocks multiple pathways involved in cancer growth and blood vessel formation, which helps delay progression. The extent of the benefit varies from person to person, depending on the cancer, liver function, and how the body tolerates treatment. Stivarga is not a cure. It works best as part of a broader care plan with regular monitoring.
As with any medication, Stivarga may cause side effects, including fatigue, hand-foot skin reaction, diarrhea, high blood pressure, and loss of appetite. Your healthcare provider will monitor your treatment and will assess whether Stivarga remains a suitable option for you.
BENEFITS
Stivarga is a treatment option for people whose HCC was previously treated with sorafenib. If earlier therapy was not enough to stop the cancer from progressing, Stivarga gives you and your provider another systemic choice. Your provider will consider your diagnosis, your earlier treatment, and your current health before deciding whether it fits your care plan.
Stivarga helps delay progression of advanced HCC. In practice, this means the goal is to keep the cancer from growing or spreading for as long as possible. The extent of this benefit varies from person to person, depending on the cancer, your liver function, and how well you tolerate treatment. Stivarga is not a cure, so your provider will keep tracking your response over time.
Stivarga blocks multiple cancer growth pathways rather than a single one. It does this by targeting kinases involved in tumor growth and in the formation of tumor blood vessels. Targeted therapy focuses on specific proteins that cancer cells use to grow, which is different from treatments that act more broadly on the body.
Stivarga is taken as a tablet, which makes dosing convenient. You take it by mouth, with a low-fat meal, at about the same time each day, exactly as prescribed. It is used in cycles, so your provider will explain which days to take it and which days to rest. Keep up your regular monitoring visits, because tablets taken at home still need close follow-up.
Report severe diarrhea or skin changes to your healthcare provider promptly. Your provider will discuss the potential benefits and risks before treatment and provide ongoing support to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of a comprehensive treatment plan alongside Stivarga. Several common side effects, such as fatigue, skin reactions, and high blood pressure, can be managed better when you watch for them early.
Report severe diarrhea or skin changes to your healthcare provider promptly.
Areas that may support treatment:
common questions
Stivarga (Regorafenib) may be prescribed for hepatocellular carcinoma (HCC) that was previously treated with sorafenib. It is a second-line systemic treatment, so your provider may consider it if your liver cancer has progressed despite earlier therapy. Your provider also checks whether you are a candidate for targeted therapy and whether Stivarga could help slow progression. Eligibility is individual, so ask your healthcare professional whether it fits your care plan.
No, Stivarga (Regorafenib) is not a cure for liver cancer. It is a therapy that helps delay progression of advanced HCC and helps control the disease. How much benefit you get varies, depending on your cancer, your liver function, and how well you tolerate treatment. Talk with your healthcare provider about realistic goals and how your response will be tracked over time.
Take Stivarga exactly as prescribed, as a tablet with a low-fat meal at about the same time each day. The usual dose is 160 mg once daily for the first 21 days of each 28-day cycle. Your healthcare provider decides the right dose for you, so follow their instructions and ask questions if anything is unclear. Store tablets at room temperature, away from moisture and heat.
Common side effects of Stivarga include fatigue, hand-foot skin reaction, diarrhea, high blood pressure, and loss of appetite. Report severe diarrhea or skin changes to your healthcare provider promptly. Treating hand-foot skin reactions early and checking your blood pressure at home can help. Your provider will discuss the potential benefits and risks with you before treatment and will support you throughout, so bring any concerns to your visits.
There is no fixed length of treatment. Stivarga is used as ongoing cyclic therapy for advanced HCC and is continued until the disease progresses or side effects become unacceptable. Your provider individualizes the duration based on your response and how well you tolerate it. Do not stop taking Stivarga on your own. Discuss any concerns about continuing treatment with your healthcare professional, who can adjust your plan to fit your needs.
Your healthcare provider will regularly monitor your liver function, your blood pressure, and how well Stivarga is working. These checks help decide whether it remains a suitable option and help catch side effects, such as high blood pressure, early. You can support monitoring by checking your blood pressure at home and reporting new symptoms. Ask your care team how often you will be seen and which tests to expect.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
